Workflow
济川药业(600566) - 2018 Q3 - 季度财报
JUMPCANJUMPCAN(SH:600566)2018-10-19 16:00

Financial Performance - Net profit attributable to shareholders rose by 44.25% to CNY 1,308,768,012.75 for the period from January to September[6] - Operating revenue for the first nine months reached CNY 5,543,988,284.65, marking a 31.57% increase year-on-year[6] - Basic earnings per share rose by 43.89% to CNY 1.613 per share[6] - The company's net profit for the period is expected to show significant growth compared to the previous year, with no warnings of potential losses[13] - Total revenue for the first nine months reached ¥5,543,988,284.65, an increase of 31.6% compared to ¥4,213,619,124.43 in the same period last year[22] - Net profit for the first nine months was ¥1,308,768,012.75, up 44.1% from ¥907,801,335.77 year-on-year[24] - Operating profit for the third quarter was ¥469,082,448.67, representing a 34.4% increase from ¥348,990,301.61 in the same quarter last year[22] Cash Flow - The net cash flow from operating activities increased by 56.88% to CNY 1,556,946,202.05 compared to the same period last year[6] - Cash and cash equivalents increased by 49.53% to CNY 1,422,955,474.69 due to increased sales collection[11] - The net cash flow from operating activities for the first nine months was CNY 1,556,946,202.05, compared to CNY 992,431,894.34 in the previous year, indicating a year-over-year increase of about 57%[29] - The cash and cash equivalents at the end of the period amounted to CNY 1,422,955,474.69, up from CNY 652,753,993.72 at the end of the same period last year, reflecting a growth of approximately 118%[30] - The net cash flow from investing activities was negative at CNY -276,474,591.62, an improvement from CNY -619,068,272.56 in the previous year, indicating a reduction in cash outflow from investments[29] - The net cash flow from financing activities was -809,126,446.58 CNY, compared to -590,857,066.50 CNY in the previous period, indicating an increase in cash outflow[33] Assets and Liabilities - Total assets increased by 13.48% to CNY 7,560,491,000.66 compared to the end of the previous year[6] - The total assets of the company reached ¥7,560,491,000.66, an increase from ¥6,662,544,812.64 at the beginning of the year[16] - The total liabilities increased to ¥2,481,770,244.51 from ¥2,260,734,140.21, reflecting a growth in financial obligations[17] - Total liabilities decreased significantly from ¥1,278,542,105.71 to ¥549,673,336.45, a reduction of 57.0%[20] - The company's intangible assets rose by 31.17% to ¥291,975,919.79, up from ¥222,594,669.79[12] Shareholder Information - The number of shareholders reached 15,391 by the end of the reporting period[9] - Jiangsu Jichuan Holding Group Co., Ltd. held 51.15% of the shares, with 37,500,000 shares pledged[9] Expenses - Research and development expenses for the first nine months were ¥144,153,625.72, up from ¥129,119,355.82 in the previous year[22] - The company reported a significant increase in sales expenses, totaling ¥2,814,142,139.02 for the first nine months, compared to ¥2,219,104,451.25 last year[22] - Financial expenses rose significantly by 133.98% to ¥3,172,954.30, compared to a negative financial expense of -¥9,338,270.29 in the previous year[12] - The company incurred financial expenses of CNY 24,366,775.55 for the first nine months, significantly higher than CNY 1,475.78 in the previous year, indicating a substantial increase in financial costs[27] Investment Performance - Investment income surged by 243.80% to ¥17,555,806.11, compared to ¥5,106,402.59 in the previous year[12] - The company reported investment income of CNY 1,238,000,000.00 for the first nine months, contributing positively to the overall financial performance[27] - The company received CNY 1,368,000,000.00 from the recovery of investments, significantly higher than CNY 350,000,000.00 in the previous year, indicating a strong performance in investment recovery[29]